This dispatch covers Ipamorelin vs. GHRP-6: Comparative Analysis of GH Secretagogues in the Growth Hormone research category, authored by Morrison, K., Liu, H., originally published in Endocrine Reviews on February 20, 2024. It has been cited 89 times and takes approximately 15 minutes to read. The Peptide Dispatch curates peer-reviewed peptide research for self-directed learners. All summaries are presented for Research Use Only and do not constitute medical advice.
Ipamorelin and GHRP-6 both bind the GHS-R1a (ghrelin) receptor and trigger pulsatile GH release, but their pharmacological selectivity diverges in ways that matter for research design. Across 28 published clinical and preclinical studies, Ipamorelin shows comparable peak GH and AUC versus GHRP-6 at molar-equivalent doses but with essentially flat cortisol, prolactin, and ACTH responses — earning its description in the literature as the 'cleaner' GH secretagogue tool. GHRP-6 reliably produces measurable cortisol (+28%) and prolactin (+22%) elevation alongside a strong subjective-hunger response that peaks 45-60 minutes post-dose and limits its utility where appetite confounds are problematic. Both peptides exhibit tachyphylaxis with sustained dosing, but the desensitisation curve appears steeper for GHRP-6. Safety signals across short-duration studies are reassuring; long-term data on insulin sensitivity, IGF-1 elevation, and oncological risk from sustained GH-axis stimulation remain limited. Neither peptide is FDA-approved for clinical use.
Growth-hormone-releasing peptides (GHRPs) are a class of synthetic ghrelin-receptor agonists that stimulate endogenous growth hormone (GH) release from the anterior pituitary. Within this class, Ipamorelin and GHRP-6 are among the most extensively researched compounds and are routinely compared in the published literature on GH secretagogue pharmacology. This meta-analysis synthesises results from twenty-eight clinical and preclinical investigations published between 1995 and 2023 that directly contrast the two peptides on three primary axes: GH-release potency and selectivity, ancillary endocrine effects (notably cortisol, prolactin, and acylated ghrelin response), and side-effect profile in human research subjects. Both peptides bind the growth-hormone secretagogue receptor (GHS-R1a) — the same receptor activated by endogenous ghrelin — and trigger pulsatile GH release that broadly mimics the natural circadian secretion pattern. However, their pharmacological profiles differ in clinically relevant ways. Ipamorelin, a pentapeptide first reported in 1998, is characterised in the literature as a 'selective' GH secretagogue: across multiple healthy-volunteer dose-response studies, single subcutaneous doses of 10-100 ug/kg produced robust GH peaks (typically 60-90 ng/mL at the higher doses) with no statistically significant elevation of cortisol, ACTH, or prolactin. This selectivity profile is the reason Ipamorelin is frequently described in research-grade literature as a 'cleaner' tool for studying isolated GH-axis biology. GHRP-6, by contrast, is a hexapeptide developed in 1980s and shares the same GHS-R1a binding mechanism but is consistently associated with measurable elevation of cortisol and prolactin alongside GH release in human research subjects. GHRP-6 also produces a strong, dose-dependent stimulation of subjective hunger — an effect attributed to its activation of orexigenic ghrelin signalling pathways in the hypothalamus — which limits its utility in resea…
All information is presented for Research Use Only (RUO). Not medical advice.